Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00349128
Recruitment Status : Completed
First Posted : July 6, 2006
Last Update Posted : September 3, 2007
Information provided by:
Solvay Pharmaceuticals

Brief Summary:
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Condition or disease Intervention/treatment Phase
Dyslipidemia/Glucose Metabolism Disorder Drug: fenofibrate and metformin combination (drug) Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 382 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.
Study Start Date : January 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Change in fasting triglycerides.

Secondary Outcome Measures :
  1. Assessment of lipid and glucose metabolisms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes mellitus

Exclusion Criteria:

  • Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00349128

  Show 51 Study Locations
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals Identifier: NCT00349128     History of Changes
Other Study ID Numbers: C LF23-0121 03 01
First Posted: July 6, 2006    Key Record Dates
Last Update Posted: September 3, 2007
Last Verified: August 2007

Keywords provided by Solvay Pharmaceuticals:
Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus

Additional relevant MeSH terms:
Metabolic Diseases
Glucose Metabolism Disorders
Lipid Metabolism Disorders
Hypoglycemic Agents
Physiological Effects of Drugs
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents